Michael Katschner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael Katschner has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chiaki Takahashi
Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan
1 shared publication - Chung Hoow Kok
Centre for Cancer Biology, College of Health, Adelaide University, Adelaide, Australia
1 shared publication - Dylan De Bellis
Flinders University
1 shared publication Emma McLennan
Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia
1 shared publication- Jack Scanlan
Mass Spectrometry & Proteomics Group, Centre for Pharmaceutical Innovation, College of Health, Adelaide University, Adelaide, South Australia, Australia
1 shared publication John Finnie
Adelaide Medical School, The University of Adelaide, North Terrace, Adelaide, SA 5005, Australia
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb2571
Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice
Hepatocyte polyploidization promotes liver homeostasis by enhancing resistance to cellular stress. Caspase-2, a proapoptotic protease, restricts polyploidization by deleting polyploid and aneuploid cells. While caspase-2 protects against diet-induced hepatic injury, it also acts as a tumor suppressor by controlling genomic instability and oxidative stress. To investigate these roles, we assessed hepatic ploidy dynamics, liver damage, and age-associated tumorigenesis in caspase-2–deficient and catalytically inactive mutant mice. We found that caspase-2 loss promotes early-onset hepatocyte hyperpolyploidy, accompanied by progressive liver inflammation, fibrosis, oxidative liver damage, ferroptosis, and higher incidence of spontaneous hepatocellular carcinoma in aged animals. Proteomic profiling revealed a pathogenic polyploidy–associated signature associated with caspase-2 deficiency and increased predisposition to liver disease and malignancy. These findings establish caspase-2 enzymatic activity as a critical regulator of hepatic genome stability and preventing age-related liver cancer that strongly argue against therapeutic caspase-2 inhibition as a strategy for managing liver injury or cancer risk.
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb2571
Open AccessCaspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice
Hepatocyte polyploidization promotes liver homeostasis by enhancing resistance to cellular stress. Caspase-2, a proapoptotic protease, restricts polyploidization by deleting polyploid and aneuploid cells. While caspase-2 protects against diet-induced hepatic injury, it also acts as a tumor suppressor by controlling genomic instability and oxidative stress. To investigate these roles, we assessed hepatic ploidy dynamics, liver damage, and age-associated tumorigenesis in caspase-2–deficient and catalytically inactive mutant mice. We found that caspase-2 loss promotes early-onset hepatocyte hyperpolyploidy, accompanied by progressive liver inflammation, fibrosis, oxidative liver damage, ferroptosis, and higher incidence of spontaneous hepatocellular carcinoma in aged animals. Proteomic profiling revealed a pathogenic polyploidy–associated signature associated with caspase-2 deficiency and increased predisposition to liver disease and malignancy. These findings establish caspase-2 enzymatic activity as a critical regulator of hepatic genome stability and preventing age-related liver cancer that strongly argue against therapeutic caspase-2 inhibition as a strategy for managing liver injury or cancer risk.